Literature DB >> 9331514

Side effects of high-dose intravenous immunoglobulins.

M Stangel1, H P Hartung, P Marx, R Gold.   

Abstract

Intravenous immunoglobulins (IVIgs) are used increasingly as therapy for neuroimmunologic and other autoimmune diseases. With broader use, the number of reported side effects also is growing. Here we review the literature on adverse reactions reported after administration of i.v.Igs. Despite a few recent reports about a high frequency of complications of IVIgs, by and large they can be considered as safe. Mild and self-limited side effects may occur, but severe complications are rare and often associated with other risk factors for these complications. A careful screening for preexisting illnesses and monitoring of some laboratory parameters can minimize the risks of IVIg therapy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9331514     DOI: 10.1097/00002826-199710000-00002

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  13 in total

Review 1.  Adverse effects of intravenous immunoglobulin therapy.

Authors:  U E Nydegger; M Sturzenegger
Journal:  Drug Saf       Date:  1999-09       Impact factor: 5.606

Review 2.  [Use of i.v. immunoglobulins in neurology. Evidence-based consensus].

Authors:  M Stangel; R Gold
Journal:  Nervenarzt       Date:  2004-08       Impact factor: 1.214

3.  Increased risk of adverse events when changing intravenous immunoglobulin preparations.

Authors:  R Ameratunga; J Sinclair; J Kolbe
Journal:  Clin Exp Immunol       Date:  2004-04       Impact factor: 4.330

Review 4.  IVIG therapy in neurological disorders of childhood.

Authors:  Juan J Archelos; Franz Fazekas
Journal:  J Neurol       Date:  2006-09       Impact factor: 4.849

Review 5.  Intravenous immunoglobulin therapy for acquired coagulation inhibitors: a critical review.

Authors:  Koji Yamamoto; Junki Takamatsu; Hidehiko Saito
Journal:  Int J Hematol       Date:  2007-05       Impact factor: 2.490

Review 6.  Multiple sclerosis.

Authors:  Richard Nicholas; Jeremy Chataway
Journal:  BMJ Clin Evid       Date:  2009-05-14

Review 7.  Adverse effects of treatment with intravenous immunoglobulins for neurological diseases.

Authors:  Matthias Wittstock; Uwe K Zettl
Journal:  J Neurol       Date:  2006-09       Impact factor: 4.849

Review 8.  Special considerations with the use of intravenous immunoglobulin in older persons.

Authors:  M Jennifer Cheng; Colleen Christmas
Journal:  Drugs Aging       Date:  2011-09-01       Impact factor: 3.923

Review 9.  [Intravenous immunoglobulins in multiple sclerosis. An update].

Authors:  S Schwarz; H-M Meinck; B Storch-Hagenlocher
Journal:  Nervenarzt       Date:  2009-08       Impact factor: 1.214

10.  Revascularization for patients with idiopathic thrombocytopenic purpura and coronary artery disease.

Authors:  Chan-Hee Lee; Ung Kim
Journal:  Korean Circ J       Date:  2014-07-25       Impact factor: 3.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.